Over 100 Total Lots Up For Auction at Two Locations - WA 11/05, PA 11/06

Sectra and Leica Biosystems first in the world to gain FDA clearance to utilize DICOM images for pathology diagnostics

Press releases may be edited for formatting or style | April 29, 2024 Health IT
LINKÖPING, Sweden, April 29, 2024 /PRNewswire/ -- International medical imaging IT and Cybersecurity company Sectra's (STO: SECT B) digital pathology solution together with Leica Biosystems, Imaging, Inc.'s Aperio GT 450 DX have received a 510(k) clearance by the US Food & Drug Administration (FDA). This is the first time an FDA clearance within digital pathology allows the use of DICOM images for pathology diagnostics, which marks a significant step towards standardization in this field.

Sectra received its first FDA clearance during the pandemic, in 2020. The pandemic made the need and value of remote work even in the field of pathology obvious and has helped boost the adoption of digital pathology in the US. Today, the value of accessing, sharing and reviewing digital images is clear and the market for digital pathology in the US, as well as other countries, is growing rapidly.

"Given the rigorous review and clearance process leading up to this point, I see the new FDA clearance as strong proof of the quality of our solution. It is also an enabler for pathology departments to benefit from the latest scanner technology as well as the standardization that is happening within digital pathology. We have already seen how our customers utilize digital pathology to improve patient care, especially in complex cases such as cancer, and I am proud to be part of that journey," says Elin Kindberg, Global Product Manager Pathology at Sectra.

The FDA clearance includes:

Sectra's digital pathology solution when used with Leica Biosystems Aperio GT 450 DX
SVS and DICOM file formats
Sectra UniView and IDS7
cloud-based and on-premises installation

"Sectra has a strong track record of promoting and enabling open integrations and of pushing the development towards standardization within medical imaging IT. The recent FDA clearance including the clearance to utilize DICOM images for pathology diagnostics therefore makes me very proud. Due to the unique nature of the images used in digital pathology, proprietary formats have previously dominated. This FDA approval, including DICOM, shows that standardization is possible also within pathology. This is an important first step to a reality where healthcare providers can start reaping the benefits of a larger degree of freedom in choosing what hardware and software to combine, within pathology. This has the potential to increase workflow efficiency, facilitate the adoption of new technology and in the end—benefit patient care," says Dr. Torbjörn Kronander, CEO and President Sectra AB.

You Must Be Logged In To Post A Comment